ALT

Altimmune Inc

ALT, USA

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

https://altimmune.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALT
stock
ALT

Stock markets fall in early trade amid geopolitical tensions, foreign fund outflows PSU Watch

Read more →
ALT
stock
ALT

Stock markets drop in early trade on relentless foreign fund outflows, geopolitical tensions PSU Watch

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$17.75

Analyst Picks

Strong Buy

5

Buy

3

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

1.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.24 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.70 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-237,940.00 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.18

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 48.20% of the total shares of Altimmune Inc

1.

BlackRock Inc

(7.2204%)

since

2025/06/30

2.

Vanguard Group Inc

(5.8546%)

since

2025/06/30

3.

State Street Corp

(3.12%)

since

2025/06/30

4.

TANG CAPITAL MANAGEMENT LLC

(3.1159%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.0883%)

since

2025/07/31

6.

Geode Capital Management, LLC

(2.1923%)

since

2025/06/30

7.

iShares Russell 2000 ETF

(2.0961%)

since

2025/08/31

8.

Susquehanna International Group, LLP

(1.8353%)

since

2025/06/30

9.

SPDR® S&P Biotech ETF

(1.4082%)

since

2025/08/31

10.

Knoll Capital Management LP

(1.2707%)

since

2025/06/30

11.

Caption Management, LLC

(1.1113%)

since

2025/06/30

12.

Federated Hermes Inc

(1.0373%)

since

2025/06/30

13.

UBS Group AG

(1.0049%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9997%)

since

2025/07/31

15.

Morgan Stanley - Brokerage Accounts

(0.9466%)

since

2025/06/30

16.

Fidelity Small Cap Index

(0.8788%)

since

2025/06/30

17.

Bank of America Corp

(0.8113%)

since

2025/06/30

18.

iShares Russell 2000 Growth ETF

(0.7628%)

since

2025/08/31

19.

Northern Trust Corp

(0.7255%)

since

2025/06/30

20.

Federated Hermes MDT Small Cap Core IS

(0.67%)

since

2025/06/30

21.

Federated Hermes MDT SCC Institutional

(0.67%)

since

2025/06/30

22.

Citadel Advisors Llc

(0.5931%)

since

2025/06/30

23.

Goldman Sachs Group Inc

(0.5657%)

since

2025/06/30

24.

iShares Biotechnology ETF

(0.551%)

since

2025/08/31

25.

Group One Trading, LP

(0.5318%)

since

2025/06/30

26.

Dimensional Fund Advisors, Inc.

(0.507%)

since

2025/06/30

27.

Two Sigma Investments LLC

(0.4955%)

since

2025/06/30

28.

Fidelity Extended Market Index

(0.4938%)

since

2025/07/31

29.

FMR Inc

(0.4553%)

since

2025/06/30

30.

Vanguard Russell 2000 ETF

(0.4191%)

since

2025/07/31

31.

Fidelity Enhanced Small Cap ETF

(0.3904%)

since

2025/08/29

32.

Beirne Wealth Consulting Services, LLC

(0.388%)

since

2025/06/30

33.

Federated Hermes MDT SCG Institutional

(0.2951%)

since

2025/06/30

34.

Federated Hermes MDT Small Cap Growth IS

(0.2951%)

since

2025/06/30

35.

State St Russell Sm Cap® Indx SL Cl I

(0.2812%)

since

2025/08/31

36.

Vanguard Health Care ETF

(0.2697%)

since

2025/07/31

37.

Vanguard Explorer Inv

(0.2226%)

since

2025/06/30

38.

Schwab Small Cap Index

(0.2205%)

since

2025/07/31

39.

NT R2000 Index Fund - NL

(0.2122%)

since

2025/06/30

40.

iShares Micro-Cap ETF

(0.1974%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2491

Latest Release

Date

2025-09-30

EPS Actual

-0.21

EPS Estimate

-0.27

EPS Difference

0.06

Surprise Percent

22.2222%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.